ENDRA Life Sciences Inc.
NDRA
$4.09
-$0.0519-1.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.77% | 19.63% | 38.24% | -22.93% | -11.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.65% | -8.26% | 2.82% | -35.54% | -24.21% |
| Operating Income | 10.65% | 8.26% | -2.82% | 35.54% | 24.21% |
| Income Before Tax | 8.36% | 1.26% | -14.39% | 25.83% | 21.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.36% | 1.26% | -14.39% | 25.83% | 21.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.36% | 1.26% | -14.39% | 25.83% | 21.79% |
| EBIT | 10.65% | 8.26% | -2.82% | 35.54% | 24.21% |
| EBITDA | 10.40% | 7.77% | -3.59% | 35.30% | 24.07% |
| EPS Basic | 85.46% | -- | -- | -- | -- |
| Normalized Basic EPS | 85.46% | -- | -- | -- | -- |
| EPS Diluted | 85.46% | -- | -- | -- | -- |
| Normalized Diluted EPS | 85.46% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 13,112.18% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 13,112.18% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |